A
Arvinas, Inc. (ARVN)
NMS – Real Time Price. Currency in USD
9.57
-0.09 (-0.93%)
At close: May 12, 2026, 4:00 PM EDT
9.53
-0.04 (-0.42%)
Pre-market: May 13, 2026, 6:13 AM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
9.57
-0.09 (-0.93%)
At close: May 12, 2026, 4:00 PM EDT
9.53
-0.04 (-0.42%)
Pre-market: May 13, 2026, 6:13 AM EDT
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
| Name | Position |
|---|---|
| Dr. Noah Berkowitz M.D., Ph.D. | Chief Medical Officer |
| Dr. Randy Teel Ph.D. | CEO, President & Director |
| Mr. Alexander A. Santini | Chief Commercial Officer |
| Mr. Andrew R. Saik | CFO & Treasurer |
| Mr. David K. Loomis M.B.A. | VP & Chief Accounting Officer |
| Mr. Jared M. Freedberg J.D. | General Counsel & Corporate Secretary |
| Mr. Jeff Boyle | Vice President of Investor Relations |
| Mr. Paul McInulty | Senior Vice President of Regulatory Affairs |
| Mr. Steve Weiss | Senior VP & Chief Human Resources Officer |
| Ms. Angela M. Cacace Ph.D. | Chief Scientific Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-01 | 8-K | arvn-20260501.htm |
| 2026-04-29 | DEFA14A | defa14a-coverx2026.htm |
| 2026-04-29 | DEF 14A | arvn-20260429.htm |
| 2026-04-29 | ARS | a2025ars.pdf |
| 2026-03-18 | 8-K | arvn-20260318.htm |
| 2026-02-24 | 8-K | arvn-20260224.htm |
| 2026-02-24 | 10-K | arvn-20251231.htm |
| 2026-02-12 | 8-K | arvn-20260210.htm |
| 2025-12-08 | 8-K | arvn-20251206.htm |
| 2025-11-05 | 10-Q | arvn-20250930.htm |